Brief: Alligator Bioscience: Data Confirm Mitazalimab's Manageable Safety Profile
22/12/2022 08:36
Dec 22 (Reuters) - Alligator Bioscience AB ATORX.ST :
* ANNOUNCES PUBLICATION HIGHLIGHTING PHASE 1 MITAZALIMAB
DATA IN
SOLID TUMORS
* DATA CONFIRM MITAZALIMAB'S MANAGEABLE SAFETY PROFILE VIA A
THOROUGH DOSE-ESCALATION APPROACH VIA INTRAVENOUS ADMINISTRATION
Source text for Eikon: ID:nMFN7ssv4v
Further company coverage: ATORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Alligator Bioscience AB
See all newsBrief: Alligator Bioscience Q1 Net Loss SEK 1.4 Million
Sweden's Alligator Bioscience posts Q1 net profit, narrows operating loss
Brief: Alligator Bioscience Q1 EBIT SEK -17.8 Million
Brief: Alligator Bioscience Signs LoI With Unicancer For Phase 3 Mitazalimab Development
Brief: Exercise Of Warrants Brings Alligator Bioscience Net Proceeds Of SEK 12 Mln